Edition:
United Kingdom

Santhera Pharmaceuticals Holding AG (SANN.S)

SANN.S on Swiss Exchange

28.65CHF
12:33pm GMT
Change (% chg)

CHF-0.60 (-2.05%)
Prev Close
CHF29.25
Open
CHF29.40
Day's High
CHF29.45
Day's Low
CHF28.60
Volume
10,285
Avg. Vol
72,754
52-wk High
CHF82.00
52-wk Low
CHF25.10

Select another date:

Thu, Feb 15 2018

BRIEF-Santhera Says Obtains Worldwide Exclusive License From Polyphor

* SANTHERA OBTAINS WORLDWIDE EXCLUSIVE LICENSE FROM POLYPHOR TO DEVELOP AND COMMERCIALIZE CLINICAL STAGE CANDIDATE FOR CYSTIC FIBROSIS AND OTHER PULMONARY DISEASES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Santhera Launches U.S. Expanded Access Program With Idebenone For Patients With DMD

* SANTHERA LAUNCHES U.S. EXPANDED ACCESS PROGRAM WITH IDEBENONE FOR PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Santhera Pharmaceuticals Holding 2017 Revenues From Sales Of Raxone Up At CHF 22.9 Million

* INCREASE OF 21% YOY IN FY NET REVENUES TO CHF 22.9 MILLION (2016: CHF 19.0 MILLION) FROM SALES OF RAXONE

BRIEF-Santhera: Negative CHMP Opinion On Appeal For Authorization Of Raxone

* SANTHERA RECEIVES NEGATIVE CHMP OPINION ON APPEAL FOR AUTHORIZATION OF RAXONE® IN DUCHENNE MUSCULAR DYSTROPHY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Shares In Santhera Pharmaceuticals Holding AG Suspended From Trading Until Further Notice‍​

Jan 24 Shares In Santhera Pharmaceuticals Holding Ag are suspended from trading until further notice - Six Swiss Exchange said.

BRIEF-Santhera: negative opinion from the CHMP for Raxone in DMD

* SANTHERA RECEIVES NEGATIVE OPINION FROM THE CHMP FOR ITS MARKETING AUTHORIZATION APPLICATION FOR RAXONE® IN DMD AND INTENDS TO APPEAL THIS OPINION

BRIEF-Santhera Pharmaceuticals Holding H1 net loss widens to CHF 22.7 million

* ‍1H 2017 SALES OF CHF 10.9 MILLION, INCREASE OF 51% COMPARED TO 1H 2016​

BRIEF-Santhera announces approval of Raxone for LHON in Israel

* SANTHERA ANNOUNCES APPROVAL OF RAXONE FOR LHON IN ISRAEL Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: